4.6 Article

Long term outcomes of pediatric Bipolar-I disorder: A prospective follow-up analysis attending to full syndomatic, subsyndromal and functional types of remission

Journal

JOURNAL OF PSYCHIATRIC RESEARCH
Volume 151, Issue -, Pages 667-675

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2022.04.008

Keywords

Bipolar disorder; Persistence; Pediatric; Adolescent; Young adult

Categories

Funding

  1. PCORI [K23MH100450]
  2. Demarest Lloyd, Jr. [667302]
  3. Johnson and Johnson [14/027,676, 10,245,271 B2]
  4. National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH)
  5. Pfizer
  6. Shire
  7. Merck
  8. NeuroMetrix
  9. NIMH
  10. RLS Foundation
  11. Otsuka
  12. Axon Labs
  13. Boehringer-Ingelheim
  14. Cantor Colburn, Covance
  15. Cephalon
  16. Eli Lilly
  17. Novadel Pharma
  18. Sanofi-Aventis
  19. Sunovion
  20. Takeda
  21. UCB
  22. Xenoport
  23. Simons Center for the Social Brain
  24. American Academy of Child and Adolescent Psychiatry, The Israeli Society of ADHD
  25. Akili Interactive Labs, Arbor, Genomind, Ironshore
  26. Alcobra
  27. Enzymotec
  28. KemPharm
  29. European Union?sHorizon 2020 research and innovation programme
  30. AACAP, Feinstein Institute for Medical Research
  31. Headspace Inc.
  32. NIDA
  33. Roche TCRC Inc.
  34. NIH
  35. Biomarin, Bracket Global
  36. Cogstate
  37. Theravance
  38. Department of Psychiatry at MGH
  39. Tris
  40. Food & Drug Administration
  41. MGH Psychiatry Academy
  42. Jazz Pharma
  43. Department of Defense
  44. PamLab
  45. Ironshore
  46. AACAP
  47. Abbott
  48. APSARD, Arbor Pharmaceuticals
  49. AstraZeneca
  50. Celltech
  51. Children?s Hospital of Southwest
  52. Florida/Lee Memorial Health System, Cipher Pharmaceuticals Inc.
  53. Forest Research Institute, Fundacion Areces (Spain)
  54. Forest, Fundacio?n Dr.Manuel Camelo A.C.
  55. Juste Pharmaceutical Spain, Magceutics
  56. Medice Pharmaceuticals
  57. Merck, MGH Psychiatry Academy, MMC Pediatric, NARSAD
  58. NIDA, New River, NICHD
  59. Noven, Neurosearch
  60. Organon
  61. Prechter Foundation
  62. Quantia Communications
  63. Stanley Foundation
  64. UCB Pharma Inc., Vaya Pharma/Enzymotec
  65. Wyeth

Ask authors/readers for more resources

This study found that remission of pediatric bipolar I disorder is rare, with most patients continuing to experience high levels of morbidity into late adolescence and early adulthood.
Objective: To examine patterns of remission of pediatric bipolar I (BP-I) disorder attending to syndromatic, symptomatic, and functional outcomes from childhood to adolescent and young adult years. Methods: We analyzed data from a six-year prospective follow-up study of youths aged 6-17 years with BP-I disorder. Subjects were comprehensively assessed at baseline and subsequently at four, five, and six years thereafter. Assessments included structured diagnostic interviews and measures of psychosocial and educational functioning. Patterns of remission were calculated attending to whether syndromatic, symptomatic, and functional remission were achieved. Results: Kaplan-Meier failure functions revealed that the probability of functional recovery from pediatric BP-I disorder was very low. Of the 88 youths assessed, only 6% (N = 5) of the sample were euthymic with normal functioning during the year prior to their last follow-up assessment (average follow-up time = 5.8 +/- 1.8 years). Conclusions: These results provide compelling evidence of the high level of persistence of pediatric BP-I disorder. Symptomatic and functional remission were uncommon and most subjects continued to demonstrate high morbidity into late adolescence and early adulthood.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available